Assessment of immunogenicity of human Melan-A peptide analogues in HLA- A*,0201/Kb transgenic mice

Journal of Immunology

Volumn 162, Issue 6, 1999, Pages 3566-3573

  Men, Ying ^a   Miconnet, Isabelle ^a   Valmori, Danila ^a   Rimoldi, Donata ^a   Cerottini, Jean Charles ^a   Romero, Pedro ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER CELL; CROSS REACTION; CYTOLYSIS; DATA ANALYSIS; HLA SYSTEM; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; MELANOMA; NONHUMAN; PRIORITY JOURNAL; TRANSGENE;

EID: 0033559673     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Romero, P. 1996. Cytolytic T lymphocyte responses of cancer patients to tumor-associated antigens. Springer Semin. Immunopathol. 18:185.
2. Van den Eynde, B. J., and P. van der Bruggen. 1997. T cell defined tumor antigens. Curr. Opin. Immunol. 9:684.
3. Coulie, P. G., V. Brichard, A. van Pel, T. Wolfel, J, Schneider, C. Traversari, S. Mattel, E. de Plaen, C. Lurquin, J. P. Szikora, J.-C. Renauld, and T. Boon, 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35.
4. Kawakami, Y., S. Eliyahu, C. H. Delgado, P. F. Robbins, L. Rivoltini, S. L. Topalian, T. Miki, and S. A. Rosenberg. 1994. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 91:3515.
5. Brichard, V., A. van Pel, T. Wolfel, E. de Plaen, B. Lethe, P. Coulie, and T. Boon. 1993. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 178:489.
6. Cox, A. L. J. Skipper, Y. Chen, R. A Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716.
7. Kawakami, Y., S. Eliyahu, C. Jennings, K. Sakaguchi, X. Kang, S. Southwood, P. F. Robbins, A. Sette, E. Appella, and S. A. Rosenberg. 1995. Recognition of multiple epitopes in the human melanoma antigen gp 100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J. Immunol. 154:3961.
8. Wang, R. F., P. F. Robbins, Y Kawakami, X. Q. Kang, and S. A. Rosenberg. 1995. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor infiltrating lymphocytes. J. Exp. Med. 181:799.
9. Kawakami, Y., S. Eliyahu, K. Sakaguchi, P. F. Robbins, L. Rivoltini, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347.
10. + cytotoxic T lymphocytes. J. Exp. Med. 181:363.
11. Romero, P., N. Gervois, J. Schneider, P. Escobar, D. Valmori, C. Pannetier, A, Steinle, T. Wolfel, D. Lienard, V. Brichard, et al. 1997. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/ MART-1 antigenic peptide in melanoma. J. Immunol. 159:2366.
12. Valmori, D., J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Lienard, D. Rimoldi, V. Jongeneel, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160:1750.
13. Jaëger, E., H. Bernhard, P. Romero, M. Ringhoffer, M. Arand, J. Karbach, C. Ilsemann, M. Hagedorn, and A. Knuth. 1996. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int. J. Cancer 66:162.
14. Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P. F. Roobins, F. M. Marincola, M. L. Salgaller, J. R. Yannelli, E. Appella, and S. A. Rosenberg. 1995. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154:2257.
15. + melanoma patients have a memory phenotype. Int. J. Cancer 78:99.
16. Van Elsas, A., S. H. van der Burg, C. E. van der Minne, M. Borghi, J. S. Mourer, C. J. M. Melief, and P. I. Schrier. 1996. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201 binding peptides from the Melan-A/MART-1 self antigen. Eur. J. Immunol. 26:1683.
17. Cormier, J. N., M. L. Salgaller, T. Pnevette, K. C. Baracchini, L. Rivoltini, N. P. Restifo, S. A. Rosenberg, and F. M. Marincola. 1997. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan-A. Cancer J. Sci. Am. 1:37.
18. Sette, A., A. Vitiello, B. Reherman, P. Fowler, R. Nayersina, W. M. Kast, C. J. Melief, C. Oseroff, L. Yuan, J. Ruppert, et al. 1994. The relationship between class 1 binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 153:5586.
19. Van dor Burg, S. H., M. J. Visseren, R. M. Brandt, W. M. Kast, and C. J. Melief. 1996. Immunogenicity of peptides hound to MHC class I molecules depends on the MHC-peptide complex stability. J. Immunol. 156:3308.
20. Ruppert, J., J. Sidney, E. Celis, R. T. Kubo, H. M. Grey, and A. Sette. 1993. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell 74:929.
21. Parkhurst, M. R., M. L. Salgaller, S. Southwood, P. F. Robbins, A. Sette, S. A. Rosenberg, and Y. Kawakami. 1996. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157:2539.
22. Bakker, A. B., S. H. van der Burg, R. J. Huijbens, J. W. Drijfhout, C. J. Melief, G. J. Adema, and C. G. Figdor. 1997. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int. J. Cancer 70:302 .
23. Vitiello, A . D. Marchesini, J. Furze, L. A. Sherman, and R. W. Chesnut. 1991. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-murine class I major histocompalibility complex. J. Exp. Med. 173:1007.
24. Diamond, D. J., J. York, J. Y. Sun, C. L. Wright, and S. J. Forman. 1997. Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90:1751.
25. 2m double knockout mice. J. Exp. Med. 185:2043.
26. Shirai, M., T. Arichi, M. Nishioka, T. Nomura, K. Ikeda, K. Kawanishi, V. H. Engelhard, S. M. Feinstone, and J. A. Berzofsky. 1995. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J. Immunol. 154:2733.
27. Man, S., M. H. Newberg, V. L. Crotzer, C. J. Luckey, N. S. Williams, Y. Chen, E. L. Huczko, J. P. Ridge, and V. H. Engelhard. 1995. Definition of a human T cell epitope from influenza A non-structural protein 1 using HLA-A2.1 transgenic mice. Int. Immunol. 7:597.
28. Schonbach, C., K. Nokihara, C. R. Bangham, A. Kariyone, S. Karaki, H. Shida, K. Takatsu, K. Egawa, K. H. Wiesmuller, and M. Takiguchi. 1996. Identification of HTLV-1-specific CTL directed against synthetic and naturally processed peptides in HLA-B*3501 transgenic mice. Virology 226:102.
29. Visseren, M. J., S. H. van der Burg, E. I. van der Voort, R. M. Brandt, P. I. Schrier, P. van der Bruggen, T. Boon, C. J. Melief, and W. M. Kast. 1997. Identification of HLA-A*0201-restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product. Int. J. Cancer 73:125.
30. Theobald, M., J. Biggs, J. Hernandez, J. Lustgarten, C. Labadie, and L. A. Sherman. 1997. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med. 185:833.
31. Zhai, Y., J. C. Yang, P. Spiess, M. I. Nishimura, W. W. Overwijk, B. Roberts, N. P. Restifo, and S. A. Rosenberg. 1997. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J. Immunother. 20:15.
32. Irwin, M. J., W. R. Heath, and L. A. Sherman. 1989. Species-restricted interactions between CD8 and the α3 domain of class I influence the magnitude of the xenogeneic response. J. Exp. Med. 170:1091.
33. Valmori, D., J. F. Romero, Y. Men, J. L. Maryanski, P. Romero, and G. Corradin. 1994. Induction of a cytotoxic T cell response by co-injection of a T helper peptide and a cytotoxic T lymphocyte peptide in incomplete Freund's adjuvant (IFA): further enhancement by pre-injection of IFA alone. Eur. J. Immunol. 24:1458.
34. Stoute, J. A., M. Slaoui, D. Gray Heppner, P. Momin, K. E. Kester, P. Desmons, B. T. Wellde, N. Garçlon, U. Krzych, M. Marchand, W. Ripley Ballou, and J. D. Cohen. 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 336:87.
35. Panina-Bordignon, P., A. Tan, A. Termijtelen, S. Demotz, G. Corradin, and A. Lanzavecchia. 1989. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 19:2237.
36. Stevens, E. J., L. Jacknin, P. F. Robbins, Y. Kawakami, M. el Gamil, S. A. Rosenberg, and J. R. Yannelli. 1995. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines: fine specificity and MART-1 melanoma antigen recognition. J. Immunol. 154:762.
37. Wentworth, P. A., A. Vitiello, J. Sidney, E. Keogh, R. W. Chesnut, H. Grey, and A. Seite. 1996. Differences and similarities in the A2.1-restricted cytotoxic T cell repertoire in humans and human leukocyte antigen-transgenic mice. Eur. J. Immunol. 26:97.
38. Man, S., J. P. Ridge, and V. H. Engelhard. 1994. Diversity and dominance among TCR recognizing peptide in human MHC class I transgenic mice. J. Immunol. 153:4458.
39. Tourdot, S., M. Oukka, J.-C. Manuguerra, N. Livaditis, I. Vergnon, N. Riche, M. Bruley-Rosset, P. Cordopatis, and K. Kosmatopoulos. 1997. Chimeric peptides: a new approach to enhance immunogenicity of peptides with low MHC binding affinity: application in viral protection. J. Immunol. 159:2391.
40. Feltkamp, M. C., H. L. Smits, M. P. Vierboom, R. P. Minnaar, B. M. de Jongh, J. W. Drijfhout, J. ter Schegget, C. J. Melief, and W. M. Kast. 1993. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:2242.
41. Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with melastatic melanoma. Nat. Med. 4:321.
42. Cabaniols, J.-P., R. Cibotti, P. Kourilsky, K. Kosmatopoulos, and J. Kanellopoulos. 1994. Dose dependent T cell tolerance to an immunodominant self peptide. Eur. J. Immunol. 8:1743.
43. Liu, G. Y., P. J, Fairchild, R. M. Smith, J. R. Prowle, D. Kioussis, and D. C. Wraith. 1995. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 3:407.
44. Poplonski, L. B. Vukusic, J. Pawling, S. Clapoff, J. Roder, N. Hozumi, and J. Wither. 1996. Tolerance is overcome in beef insulin-transgenic mice by activation of low-affinity autoreactive cells. Eur. J. Immunol. 26:601.
45. Ohashi, P. S., S. Oehen, K. Buerki, H. Pircher, C. T. Ohashi, B. Odrmatt, B. Malissen, R. M. Zinkernagel, and H. Henganner. 1991. Ablation of tolerance and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65:305.
46. Oldstone, M. B. A., M. Nerenberg, P. Southern, J. Price, and H. Lewicki. 1991. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65:319.
47. De Bruijn, M. L., D. H. Schuurhuis, M. P. Vierboom, H. Vermeulen, K. A. de Cock, M. E. Ooms, M. E. Ressing, M. Toebes, K. L. Franken, J. W. Drijfhout, et al. 1998. Immunization with human papillomavirus type 16 (HPV 16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I-restricted protection to HPV16-induced tumor cells. Cancer Res. 58:724.
48. Bellone, M., G. Iezzi, A. Martin-Fontecha, L. Rivolta, A. A. Manfredi, M. P. Protti, M. Freschi, P. Dellabona, G. Casorati, and C. Rugarli. 1997. Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells. J. Immunol. 158:783.
49. Nair, S. K., D. Boczkowski, D. Snyder, and E. Gilboa. 1997. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur. J. Immunol. 27:589.
50. Mayordomo, J. I., D. J. Loftus, H. Sakamoto, C. M. De Cesare, P. M. Appasamy, M. T. Lotze, W. J. Storkus, E. Appella, and A. B. DeLeo. 1996. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med. 183:1357.
51. Celluzzi, C. M., J. I. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falo, Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:283.
52. Mandelboim, O., E. Vadai, M. Fridkin, A. Katz-Hillel, M. Feldman, G. Berke, and L. Eisenbach. 1995. Regression of established murine carcinoma metastases following vaccination with tumor-associated antigen peptides. Nat. Med. 1:1179.
53. Tocs, R. E., R. Offringa, R. J. Blom, C. J. Melief, and W. M. Kast. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 93:7855.
54. Aichele, P., K. Brduscha-Riem, R. M. Zinkernagel, H. Hengartner, and H. Pircher. 1995. T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med. 182:261.
55. Toes, R. E., R. J. Blom, R. Offringa, W. M. Kast, and C. J. Melief. 1996. Enhanced tumor outgrowth after peptide vaccination: functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156:3911.
56. Romero, P., R. Dunbar, D. Valmori, M. Pittet, G. S. Ogg, D. Rimoldi, J.-L. Chen, D. Lienard, J.-C. Cerottini, and V. Cerundolo. 1998. Ex-vivo staining of metastatic lymph nodes by class I MHC tetramers reveals high numbers of antigen-experienced tumor specific CTL. J. Exp. Med. 188:1641.